Brian G. Feagan
0000-0002-6914-3822
Publication & Citation Trends
Publications
0 total
Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn’s disease: rationale, design and protocol for the randomised controlled VECTORS trial
Cited by 0
Semantic Scholar
Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib.
Cited by 0
Semantic Scholar
TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH RO7790121 DEMONSTRATES EARLY CLINICAL RESPONSE AND SYMPTOM IMPROVEMENT – RESULTS FROM THE PHASE 2B TUSCANY-2 TRIAL
Cited by 2
Semantic Scholar
Tu1933: INFECTION ADVERSE EVENTS WITH TULISOKIBART OVER 50 WEEKS OF TREATMENT IN THE PHASE 2 CROHN’S DISEASE APOLLO-CD TRIAL
Cited by 0
Semantic Scholar
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
Cited by 10
Semantic Scholar
Early and sustained improvement in patient-reported outcomes and biomarker concentrations with tulisokibart induction in patients with moderately to severely active ulcerative colitis: a post-hoc analysis from ARTEMIS-UC
Cited by 0
Semantic Scholar
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease
Cited by 0
Semantic Scholar
Tu1859: PHARMACOKINETIC COMPARABILITY AND SAFETY BETWEEN ORIGINAL AND CITRATE-FREE MIRIKIZUMAB FORMULATIONS FOR SUBCUTANEOUS INJECTIONS: RESULTS FROM THREE CLINICAL TRIALS IN HEALTHY PARTICIPANTS
Cited by 0
Semantic Scholar
Research Topics
Inflammatory Bowel Disease
(1024)
Microscopic Colitis
(685)
Eosinophilic Esophagitis
(186)
Autoimmune and Inflammatory Disorders
(128)
Immunodeficiency and Autoimmune Disorders
(120)
Affiliations
Semmelweis University
Ontario Institute for Cancer Research
University of North Carolina at Chapel Hill
Western University
Cedars-Sinai Medical Center